$CTNM News

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain

Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medicinal Chemistry

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet

Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum Therapeutics Announces Its Phase 1b Study Of PIPE-791 Meets Primary Endpoint By Demonstrating At Least 30% Reduction In Chronic Pain

We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth

Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway

Contineum Therapeutics Q4 Earnings Summary & Key Takeaways

Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate